Le azioni di Pyxis Oncology scendono dopo il taglio del target price da parte di RBC per dati di trial complessi
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma - Slideshow (NASDAQ:PYXS) 2025-12-18